Bexxar Retreatment, Leukemia Reports Among Corixa’s Phase IV Studies
Executive Summary
Corixa will examine the retreatment effects of Bexxar patients who have had a duration of response against non-Hodgkin's lymphoma of at least six months as part of its Phase IV commitments for the oncologic
You may also be interested in...
GSK/Corixa Bexxar Video Draws FDA Warning Letter
A GlaxoSmithKline/Corixa video suggesting that Bexxar specifically targets non-Hodgkin's lymphoma cells is the subject of an FDA warning letter issued March 16
GSK/Corixa Bexxar Video Draws FDA Warning Letter
A GlaxoSmithKline/Corixa video suggesting that Bexxar specifically targets non-Hodgkin's lymphoma cells is the subject of an FDA warning letter issued March 16
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA closed out the first half of 2003 with nine new molecular entities and six major biologic approvals, putting the agency well ahead of where it was at the same time last year, according to an analysis by F-D-C Reports' Pharmaceutical Approvals Monthly